Thursday September 26, 2013
2:30 - 3:30 p.m. Eastern Time
View The Video Now
RNA-sequencing technology provides an abundance of data on the transcriptional landscape of cells and tissues, but presents a daunting task of interpreting this data in biological contexts. This webinar will present data on RNA-sequencing of triple-negative breast cancers (TNBCs) compared to microdissected normal breast tissues. TNBCs—defined as those lacking receptors for estrogen, progesterone and human epidermal growth factor—account for 15 percent of all breast cancers cases in the United States. Because of the absence of such therapeutic targets, these patients on average have a poorer overall survival rate compared to other breast cancer subtypes. Using RNA-Seq and Ingenuity® Pathway Analysis (IPA®), we demonstrate how comprehensive network and pathway analysis revealed novel insights into the tumor biology of this disease and has informed rational drug targeting for therapeutic development.
As an attendee you will learn
- How to quickly and easily interpret RNA-Seq gene-expression data in a biological context based on relevant findings from the literature
- How to adopt an integrated approach to statistical and biological analysis that will allow rapid identification of key pathways, processes, and diseases related to differentially expressed genes
- How to use novel approaches to quickly customize analysis results and identify findings most relevant to your research
Meet the Speaker:
DR. MILAN RADOVICH is an assistant professor in the Department of Surgery at the Indiana University School of Medicine. He is also a member of the IU Simon Cancer Center, the IU Center for Computational Biology and Bioinformatics, and the Indiana Institute for Personalized Medicine. His research focuses on the use of next-generation sequencing in translational oncology. In particular, his laboratory concentrates on the use of next-generation sequencing for drug development and pharmacogenomics, and for understanding mutational causes of cancer. In addition, a major focus of his work is the integration of next-generation sequencing into cancer clinical trials, with a special focus on using genomics for precision medicine.